盆腔阳性宫颈癌预防性腹主动脉旁放疗对比盆腔放疗的II期随机试验
PRO-PARA为II/III期开放标签多中心随机对照试验,针对影像学盆腔淋巴结阳性的宫颈癌患者,比较预防性腹主动脉旁放疗与单纯盆腔放疗(均联合同步化疗及近距离治疗)能否降低腹主动脉旁复发风险,目前为II期主要终点阶段。
要点
- 盆腔淋巴结阳性宫颈癌腹主动脉旁失败率高于阴性者,预防性照射可能获益。
- II期主要终点为腹主动脉旁复发风险降低,达标后启动III期。
- 两臂均接受顺铂40 mg/m2每周同步化疗及HDR近距离治疗。
核心结论
- 本试验旨在验证盆腔淋巴结阳性宫颈癌中预防性腹主动脉旁照射能否降低腹主动脉旁复发风险。
研究设计与样本
- 两臂平行组、II/III期开放标签多中心随机对照试验,II期主要终点为腹主动脉旁复发风险降低,达标后启动III期。
关键数值与推荐
- 对照组(A臂)盆腔放疗覆盖髂总淋巴结,IMRT 45 Gy/25次/5周,影像学受累淋巴结SIB推量至55 Gy/25次。
- 试验组(B臂)盆腔及选择性腹主动脉旁放疗至肾静脉下缘,IMRT 45 Gy/25次/5周,受累淋巴结SIB推量至55 Gy/25次。
- 两臂同步化疗为顺铂40 mg/m2每周,外照射期间给予;后续行HDR腔内或腔内联合组织间插植近距离治疗。
临床怎么用
- 若II期达到主要终点,预防性腹主动脉旁照射可能成为盆腔淋巴结阳性宫颈癌的同步放化疗组成部分。
局限性
- 当前为II期阶段,III期尚未启动,疗效与安全性结论待后续数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: EMBRACE and Retro EMBRACE studies have shown that excellent local control and pelvic control could be achieved with concurrent chemoradiation and MRI-based brachytherapy in carcinoma cervix. Para-aortic nodal failure rates are higher in pelvic node-positive cases as compared to pelvic node-negative cases as demonstrated in EMBRACE studies. The current study aims to find out the benefit of adding prophylactic para-aortic node irradiation in patients of carcinoma cervix who have involved pelvic nodes on volumetric imaging. METHODS: This will be a two-arm, parallel group, phase II/III open-label multicenter randomized controlled trial. Patients will be enrolled in a phase II trial where the primary endpoint will be demonstration of reduction in the risk of para-aortic recurrence. If the primary endpoint is met, a phase III trial will be initiated using the same trial design and intervention. Patients in arm A (control arm) will receive pelvic radiotherapy covering the common iliac nodes with Intensity Modulated Radiotherapy (IMRT) to a dose of 45 Gy/25 fractions over 5 weeks. Radiologically involved lymph nodes will be boosted to a dose of 55 Gy/25 fractions with simultaneous integrated boost (SIB). Patients in arm B (Experimental arm) will receive pelvic and elective para-aortic radiotherapy up to the lower border of the renal vein (IMRT) to dose of 45 Gy/25 fractions over 5 weeks. Radiologically involved lymph nodes will be boosted to a dose of 55 Gy/25 fractions with simultaneous integrated boost (SIB). Concurrent chemotherapy with cisplatin 40 mg/m2 weekly will be given during external beam radiotherapy in both the arms. After completion of concurrent chemoradiation, high dose rate (HDR) intracavitary or intracavitary + interstitial brachytherapy will be performed in both the arms. DISCUSSION: This trial will demonstrate the efficacy of prophylactic para-aortic radiation in pelvic node-positive carcinoma cervix. It also gives an opportunity to standardize and assess the quality-assurance radiotherapy practices in carcinoma cervix across multiple premier institutes of the nation at the same time. TRIAL REGISTRATION: Clinical Trial Registry of India (CTRI): CTRI/2023/08/057075. Registered on 30th August 2023.
引用
- Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA). Trials. 2026. PMID: 41792812. doi:10.1186/s13063-026-09618-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。